Meniere’s Disease Pipeline Research Report 2021: Comprehensive Insights About 10+ Companies and 10+ Pipeline Drugs – ResearchAndMarkets.com
November 25, 2021DUBLIN–(BUSINESS WIRE)–The “Meniere’s Disease – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering.
This “Meniere’s Disease – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Meniere’s Disease pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
A detailed picture of the Meniere’s Disease pipeline landscape is provided which includes the disease overview and Meniere’s Disease treatment guidelines.
The assessment part of the report embraces, in depth Meniere’s Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Meniere’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Meniere’s Disease R&D. The therapies under development are focused on novel approaches to treat/improve Meniere’s Disease.
Meniere’s Disease Emerging Drugs Chapters
This segment of the Meniere’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Meniere’s Disease Emerging Drugs
OTIVIDEX: Otonomy
OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone. The drug is in clinical development for the treatment of Meniere’s disease. OTIVIDEX has been granted Fast Track designation for Meniere’s disease by the FDA.
SPI-1005: Sound Pharmaceuticals
SPI-1005 is an investigational new drug that contains ebselen, a novel small molecule that mimics and induces the activity of Glutathione Peroxidase (GPx) in the inner ear, retina, brain, lung, and kidney. SPI-1005 represents a novel class of anti-inflammatory and is under clinical investigation in several neurotologic diseases where GPx activity is reduced including sensorineural hearing loss, tinnitus, ototoxicity, Meniere’s disease, and in neuropsychiatric disease including bipolar mania and treatment-resistant depression. SPI-1005 is entering pivotal Phase 3 trials for the treatment of Meniere’s disease and is currently in a Phase 2b study involving Cystic Fibrosis patients with acute respiratory infections receiving IV antibiotics.
Key Questions Answered
- How many companies are developing Meniere’s Disease drugs?
- How many Meniere’s Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Meniere’s Disease?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Meniere’s Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Meniere’s Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Otonomy
- Synphora
- Sound Pharmaceuticals
- Auris Medical
- Apsen Farmaceutica
- Orbis Biosciences
- Quark Pharmaceuticals
Key Products
- OTIVIDEX
- Latanoprost intratympanic
- SPI-1005
- Betahistine intranasal
- APSLXR
- ORB 202
- QPI-1017
Key Topics Covered:
Introduction
Executive Summary
Meniere’s Disease: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Meniere’s Disease – Analytical Perspective
In-depth Commercial Assessment
- Meniere’s Disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Meniere’s Disease Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
- Comparative Analysis
OTIVIDEX: Otonomy
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
Betahistine intranasal: Auris Medical
- Product Description
- Research and Development
- Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
APSLXR: Apsen Farmaceutica
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Key Companies
Key Products
Unmet Needs
Market Drivers and Barriers
Future Perspectives and Conclusion
Analyst Views
Appendix
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/8ixi5f
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900